Yes, you can buy your own continuous glucose monitor in the US without a diabetes diagnosis, but what you can buy depends on where you look. Walk into a pharmacy with a valid prescription and a sensor like the Dexcom Stelo or Abbott Lingo costs about USD 25 to 50 for a two-week supply. Buy directly from the manufacturer or a telehealth service and no prescription is needed for over-the-counter models, though you will pay USD 89 to 99 monthly out of pocket. Insurance rarely covers a purchase without a diabetes diagnosis, and only a few prescription brands are FDA-cleared for non-diabetic use.
How Continuous Glucose Monitors Measure Glucose Beneath the Skin
A continuous glucose monitor does not measure blood. It measures interstitial fluid, the thin layer of liquid bathing your cells, using a fine filament sensor inserted roughly 5 millimeters under the skin. The filament carries an enzyme, glucose oxidase, that reacts with glucose and generates a tiny electrical current proportional to glucose concentration. The transmitter converts that current into a reading every 1 to 5 minutes and sends it to your phone.
The lag matters more than most buyers realize. Glucose moves from blood into interstitial fluid at a finite rate, so a CGM reading trails a fingerstick by about 5 to 15 minutes when glucose is changing fast. During a rapid rise after a meal, the sensor may read 20 to 40 mg/dL lower than a simultaneous blood drop. This is a measurement property, not a defect.
Every CGM still requires calibration against capillary blood at times, though factory-calibrated models have reduced this. The FDA has cleared some sensors to make treatment decisions without fingersticks, but that clearance applies to specific prescription devices used as labeled, not to every over-the-counter sensor on the shelf.
In plain terms: the sensor reads a fluid that lags your blood by minutes, so single readings during rapid change can look wrong even when the device is working.
Who Can Legally Buy a CGM Without a Prescription
The regulatory picture changed substantially between 2024 and 2026. The FDA cleared the first over-the-counter CGM, Dexcom Stelo, in March 2024 for adults not using insulin. Abbott's Lingo followed for general wellness use. These devices can be purchased by anyone 18 or older with no prescription, no diagnosis, and no clinician involvement.
Prescription CGMs, including the Dexcom G7 and Abbott FreeStyle Libre 3, still require a clinician's order. Their labeling is written for diabetes management, and their software flags low and high glucose against thresholds tuned for people on glucose-lowering medication. Using one without a prescription through a gray-market reseller is possible but leaves you without labeled guidance.
Age is a hard line. Over-the-counter sensors are cleared for adults 18 and older; pediatric use requires a prescription device and clinician oversight. Pregnancy is another edge case: no OTC sensor is cleared for gestational diabetes management, and self-monitoring during pregnancy without obstetric input carries real risk.
| Purchase Route | Prescription Needed | Typical Cost | Who It Suits |
|---|---|---|---|
| OTC sensor (Stelo, Lingo) | No | USD 89 to 99 per month | Curious adults, prediabetes, wellness tracking |
| Prescription CGM, insured | Yes | USD 0 to 60 copay per month | Diagnosed diabetes with coverage |
| Prescription CGM, cash | Yes | USD 300 to 400 per month | Diagnosed diabetes without coverage |
| Telehealth plus prescription | Yes (via clinician) | USD 150 to 250 first month | People wanting interpretation support |
| Gray-market resale | No | USD 60 to 120 per sensor | Not recommended; no support or warranty |
What Your Numbers Actually Mean: The Quantified Context
A single CGM trace produces about 1,440 readings per day at 1-minute intervals, or roughly 288 at 5-minute intervals. That volume is both the technology's strength and its trap. Normal fasting glucose sits around 70 to 99 mg/dL. After a typical mixed meal, healthy adults peak between 120 and 140 mg/dL at roughly 45 to 90 minutes, then return toward baseline within 2 to 3 hours.
The metric that predicts complications best is not the peak but time in range, the percentage of readings between 70 and 180 mg/dL. For adults with diabetes, the international consensus target is above 70 percent time in range, with time below 70 mg/dL kept under 4 percent. For people without diabetes, most spend above 95 percent of the day in that band.
For context on scale, an A1c of 7 percent corresponds to an average glucose near 154 mg/dL, while 6 percent corresponds to about 126 mg/dL. A CGM-derived glucose management indicator estimates A1c from average sensor glucose, but it can diverge from a lab A1c by 0.3 to 0.5 percentage points in people with anemia or kidney disease.
Reading the Curve: A Timeline From Insertion to Insight
The experience of using a CGM follows a predictable arc, and knowing it prevents the common mistake of judging a sensor in its first day.
| Time After Insertion | What Happens | What to Expect |
|---|---|---|
| 0 to 2 hours | Sensor hydrates; warm-up period | No readings or a startup countdown |
| 2 to 24 hours | Early signal stabilizes; insertion trauma settles | Occasional erratic readings; do not overinterpret |
| Day 1 to 3 | Sensor settles into steady performance | Reliable trend data begins |
| Day 3 to 7 | Peak accuracy window; best for pattern spotting | Compare trends, not single points |
| Day 7 to 10 | Late-life drift possible in some sensors | Accuracy may soften near wear end |
| Day 10 to 15 | Sensor expiry (varies by model, 10 to 15 days) | Replace per label; worn sensors degrade |
| Week 2 onward | Multi-sensor patterns emerge | Meals, sleep, exercise effects become visible |
The first 24 hours are the least trustworthy, which is why a single scary reading on day one should not prompt panic. In plain terms: give the sensor a couple of days before you draw conclusions.
Why the Same Meal Produces Different Curves
Two people can eat identical meals and see peaks 60 mg/dL apart. The variables driving this are well established but widely underappreciated by first-time buyers. Meal composition matters: adding fat and protein to a carbohydrate load typically blunts and delays the peak rather than eliminating it. Food order matters too; eating vegetables and protein before starch can lower the post-meal peak by 20 to 40 mg/dL in some studies.
Physical activity is the other big lever. A 15-minute walk after a meal can lower the glucose excursion measurably, and muscle contraction pulls glucose out of the blood independent of insulin. Sleep debt and stress raise morning glucose through cortisol, which is why a bad night often shows up as a higher fasting reading.
A non-obvious and often-corrected misconception: a "spike" to 160 mg/dL after a meal is not automatically harmful in a person without diabetes. Post-meal excursions of that size occur in healthy adults. What distinguishes metabolic dysfunction is impaired return to baseline, not the peak itself. Chasing flat lines with restrictive eating can backfire.
What to Actually Do Before You Buy and After
- Decide your purpose first. If you have diabetes, work through your clinician and insurer so the device is prescription-labeled and interpretation is supported.
- If you are curious or prediabetic, start with an OTC sensor for one to two months rather than indefinitely; a defined window produces patterns you can act on.
- Confirm the model's clearance and label with the manufacturer, including age limits and whether it is cleared for treatment decisions.
- Plan to review trends, not single readings, and pair the data with a clinician or dietitian if you have any metabolic diagnosis.
- Never adjust insulin or other glucose-lowering medication based on an OTC sensor; those devices are not labeled for dosing.
- Budget realistically: OTC use runs USD 89 to 99 monthly, while cash-pay prescription sensors cost USD 300 to 400 monthly.
Watch for these warning signs and stop self-managing if any appear:
- Sensor readings below 54 mg/dL or above 250 mg/dL that do not match how you feel
- Symptoms of low blood sugar (shakiness, confusion, sweating) regardless of what the sensor says
- Persistent readings that conflict with fingerstick blood glucose by more than 20 percent
- Any plan to change diabetes medication based on a non-prescription device
- Skin reactions, infection, or bleeding at the insertion site
What a CGM Cannot Tell You
A CGM is a trend tool, not a diagnostic instrument. It cannot diagnose diabetes or prediabetes; those require fasting glucose, A1c, or an oral glucose tolerance test interpreted by a clinician. It cannot detect hypoglycemia unawareness in a way that substitutes for clinical assessment. Its accuracy degrades in certain states, including significant anemia, dehydration, and high doses of vitamin C or acetaminophen with some sensor chemistries.
Cost and access remain the practical limits. No major US insurer routinely covers a CGM for a person without a diabetes diagnosis as of late 2026, so the OTC route is genuinely out of pocket. The technology is real and useful, but the decision to buy should rest on a clear purpose and realistic expectations about what 1,440 daily readings can and cannot resolve.